A brain tech company originating from Osaka University. Developed the world's first wireless implantable BCI connecting the brain to devices, realizing future healthcare where devices can be operated by thought alone. Pioneering new communication methods for people with illnesses or disabilities that make conversation or movement difficult.
The heart is an organ upon which life itself depends. With a commitment to providing new treatment options for heart failure and saving many lives, iHeart Japan is developing regenerative medicine products using iPS cells. Our product, IHJ-301, combines cells derived from iPS cells, including cardiomyocytes and endothelial cells, with a biomaterial, enabling long-term survival following implantation onto the heart and is expected to deliver strong therapeutic efficacy. Going forward, we plan to commercialize this product in Japan and internationally, with the aim of realizing a society in which patients can be saved without heart transplantation.
QioN is developing breakthrough technology to produce ammonia—used as fertilizer and clean fuel—anywhere and at low cost. Their proprietary process uses renewable energy and locally available raw materials to generate ammonia with greater energy efficiency than conventional methods. It also enables small-scale production potentially at less than half the cost. The company aims to capture 15% of the global ammonia market (over 1.5 million tons/year) and contribute to reducing both CO2 emissions and geopolitical risk associated with the supply.
Development and manufacturing of multifunctional photocatalytic coating agents and provision of related technologies.
A startup manufacturing high-quality GeO2 substrates for next-generation power semiconductors that reduce power loss using proprietary technology. It provides stable supply of materials that were previously difficult to obtain, supporting efficient power conversion for realizing GX.
